Development of new high-throughput technology and combinatorial therapeutic strategy applicable to Huntington's disease and other amyloidoses
Moduler l’agrégation de protéines amyloïdes est thérapeutiquement pertinent (p. ex. la polyneuropathie amyloïde familiale traitée avec le Tafamidis). Cependant, pour de nombreuses amyloïdoses, il n’existe pas encore de modulateur d'agrégation efficace pour thérapie. Il a été récemment montré qu...
Main Author: | Aviolat, Hubert |
---|---|
Other Authors: | Strasbourg |
Language: | en |
Published: |
2015
|
Subjects: | |
Online Access: | http://www.theses.fr/2015STRAJ037 |
Similar Items
-
Natural Genetic Variation in Yeast Reveals That NEDD4 Is a Conserved Modifier of Mutant Polyglutamine Aggregation
by: Theodore W. Peters, et al.
Published: (2018-11-01) -
Sex-dependent impaired locomotion and motor coordination in the HdhQ200/200 mouse model of Huntington's Disease
by: Jessica K. Cao, et al.
Published: (2019-12-01) -
A human single-chain Fv intrabody preferentially targets amino-terminal huntingtin fragments in striatal models of Huntington's disease
by: Todd W. Miller, et al.
Published: (2005-06-01) -
Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease
by: Emma Hockly, et al.
Published: (2006-01-01) -
Identification of brain substrates of transglutaminase by functional proteomics supports its role in neurodegenerative diseases
by: William André, et al.
Published: (2017-05-01)